Publication | Closed Access

Pioglitazone produces rapid and persistent reduction of vascular inflammation in patients with hypertension and type 2 diabetes mellitus who are receiving angiotensin II receptor blockers

InflammationMetabolic SyndromeHypertensionPersistent ReductionCardiovascular DiseaseMedicineVascular InflammationDiabetesImmunologyAntihypertensive TherapyVascular BiologyPharmacotherapyDiabetes MellitusMicrovascular DysfunctionPharmacologyAtherosclerosis